Dauntless

A better way to develop drugs.

Our one-asset, one-company model facilitates operational efficiency, drug development speed, and a simplified business development structure.

LEARN MORE

A better way to develop drugs.

Our one-asset, one-company model facilitates operational efficiency, drug development speed, and a simplified business development structure.

LEARN MORE

A better way to develop drugs.

Our one-asset, one-company model facilitates operational efficiency, drug development speed, and a simplified business development structure.

LEARN MORE

A better way to develop drugs.

Our one-asset, one-company model facilitates operational efficiency, drug development speed, and a simplified business development structure.

LEARN MORE

A better way to develop drugs.

Our one-asset, one-company model facilitates operational efficiency, drug development speed, and a simplified business development structure.

Learn More

RECENT NEWS

Dauntless Pharmaceuticals Announces Positive Data from Phase 1 Study Investigating Octreotide Formulation for Intranasal Delivery »

Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery »

Structured partnerships for pharma

We provide a creative way to advance programs that may not be funded within existing pharmaceutical research budgets. We license the asset from pharmaceutical and biotechnology companies, finance the development of the program, and provide a mechanism for the licensor to regain rights on clinical success. With this approach, Dauntless provides an effective way to add value to assets that might otherwise lie fallow.

Intense focus – one asset at a time

With our unique model, there’s no competition between assets, no internal backlogs, no de-prioritization of asset development. Inventors are guaranteed their asset is the sole focus of their team, getting the attention and funding it needs.

Optimized returns to inventors and investors

Our experience and success at launching and funding new biotech companies through a broad venture capitalist network allow us to raise capital quickly to form and grow focused asset companies and to sell or partner assets more easily.